hotspot -WSS

hotspot

author：fashion 2025-08-23 05:02:32 - browse：5

Cambridge: AbbVie — Ruby Wallau for STAT

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Medicare Advantage proposed rates disappoint insurers

WSS

What should King Charles tell the public about his cancer?

Hundreds died while taking an arthritis drug, but nobody alerted patients

To avoid data mishandling cases, universities eye AI and other tools

A disappointing year of Humira biosimilars

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Bird flu reported in person exposed to presumably infected cattle

knowledge

hotspot

focus

Trump demands the U.S. pay no more for drugs than other countries … again

'Revelatory' study finds a smoking impact that remains after quitting

Hepatitis C has a cure — but many Americans still lack access to it

Bird flu in dairy cattle: New measures to control spread to humans

ChatGPT in medicine: STAT answers readers' burning questions

KalVista pill reduced swelling 'attacks' caused by genetic disease

Jerome Adams on the need for new antivirals for Covid

Mass General Brigham physicians react to latest merger step

BioMarin wins approval for gene therapy to treat hemophilia A

BioAge raises $170M for combination therapy with Zepbound

knowledge

What should King Charles tell the public about his cancer?

Bird flu reported in person exposed to presumably infected cattle

First Opinion on colorectal cancer screening: letter and response

Four alarming medical procedures we’re glad history forgot

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Senators start work on Medicare physician payment reform

focus

leisure time

focus

entertainment